Thrombophilia laboratory findings

Jump to navigation Jump to search


Thrombophilia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombophilia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombophilia laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombophilia laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombophilia laboratory findings

CDC on Thrombophilia laboratory findings

Thrombophilia laboratory findings in the news

Blogs on Thrombophilia laboratory findings

Directions to Hospitals Treating Thrombophilia

Risk calculators and risk factors for Thrombophilia laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Asiri Ediriwickrema, M.D., M.H.S. [2]

Overview

  • There are specific laboratory findings associated with each inherited thrombophilias[1].
  • Refer to page on screening for recommendations regarding when to pursue thrombophilia testing.

Laboratory Findings

Variability in thrombophilia testing

  • Warfarin decreases protein C and S levels.
  • Heparin decreases antithrombin activity and lead to false positive results for lupus anticoagulant.
  • Direct acting oral anticoagulants can interfere with evaluation for lupus anticoagulant, antithrombin activity, protein C, and S levels.
  • Acute thrombosis: Decreases antithrombin, protein C, and protein S levels.
  • Pregnancy, liver disease, nephrotic syndrome, chemotherapies (L-asparaginase), anticoagulants, disseminated intravascular coagulation, and systemic illness can alter coagulation factor levels.

Timing

  • Given the variability discussed above, timing is important to accurately evaluate for certain thrombophilic states[2][3].
  • Acute thrombosis can affect levels of coagulation factors, therefore, testing should be delayed for approximately six months.
  • Anticoagulation can affect certain tests, and should be completed approximately four weeks after completion of anticoagulation.
  • Avoid testing during severe illness.
  • Pregnancy, oral contraceptives, hormone replacement therapy and cancer chemotherapy may also affect some tests.
  • Factor V Leiden and Prothrombin mutation can be done in patients on anticoagulants and even in acute phase, as these are genetic (PCR) tests.

Type of tests

Tests for thrombophilia are categorized according to their priority, as summarized below.

  • High priority testing should be conducted if screening conditions are met.
  • Intermediate and low priority testing should be completed in the approprate clinical context.
Priority Timing Test Associated Diagnosis
High Complete blood count General
Coagulation studies: INR, prothrombin time, partial thromboplastin time General
Factor V Leiden mutation studies Factor V Leiden
Prothrombin 20210 gene mutation Prothrombin G20210A
Lupus anticoagulant Antiphospholipid syndrome
Anticardiolipin antibodies Antiphospholipid syndrome
Delay 6 months Functional assay for antithrombin (antithrombin-heparin co-factor assay) Antithrombin deficiency
Delay 6 months Protein C functional assay (preferred over plasma protein levels) Protein C deficiency
Delay 6 months Free protein S immunoassay Protein S deficiency
Intermediate Factor VIII level (use c-reactive protein as control) Factor VIII disorders
Flow cytometry Paroxysmal nocturnal hemoglobinuria
Peripheral blood smear, JAK2 mutation studies Myeloproliferative disorders
Homocysteine level Hyperhomocysteinemia
Vitamin B12 level Hyperhomocysteinemia
Low Thrombin time General/Fibrinogen disorders
Fibrinogen level Fibrinogen disorders
Reptilase time General/Fibrinogen disorders
Plasminogen level Plasminogen disorders
Factor IX activity Factor IX disorders
Factor X activity Factor X disorders

References

  1. Seligsohn U, Lubetsky A (2001). "Genetic susceptibility to venous thrombosis". N Engl J Med. 344 (16): 1222–31. doi:10.1056/NEJM200104193441607. PMID 11309638.
  2. Cohoon KP, Heit JA (2014). "Inherited and secondary thrombophilia". Circulation. 129 (2): 254–7. doi:10.1161/CIRCULATIONAHA.113.001943. PMC 3979345. PMID 24421360.
  3. Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M; et al. (2016). "Guidance for the evaluation and treatment of hereditary and acquired thrombophilia". J Thromb Thrombolysis. 41 (1): 154–64. doi:10.1007/s11239-015-1316-1. PMC 4715840. PMID 26780744.

Template:WH Template:WS